Supplementary data The following are the Supplementary data to this article: References 1.Nauck M.A., Mirna A.E.A., Quast D.R
This insight helps your provider select semaglutide, tirzepatide, or GLP-Squaredthe medication most likely to deliver weight loss results for your unique genetic predispositions
Accordingly, GLP-1 agents are not currently recommended for colorectal cancer prevention in clinical guidelines
E.SmithA
Meanwhile, research on the mechanism and efficacy of GLP-1R/GIPR dual agonists and GLP-1R/GIPR/GCGR triple agonists paves the way to a ground-breaking therapy specific for obesity, which suggests multi-target drugs may have more advantages than a single target
Funding The authors declare no grants or financial support for the research, authorship, and publication of this article